MEMORANDUM FOR SECRETARY OF THE NAVY
SECRETARY OF THE AIR FORCE
COMMANDER, ARMY MATERIEL COMMAND
COMMANDER, ARMY MEDICAL COMMAND
COMMANDER, ARMY TEST AND EVALUATION COMMAND

SUBJECT: Immediate Safety Review and Extension of Moratorium

1. Effective immediately, as the DoD Executive Agent for the DoD Biological Select Agent and Toxin (BSAT) Biosafety Program, I direct a safety review at all DoD laboratories and facilities involved in the production, shipment, and handling of any live or inactivated BSAT, or derivatives of BSAT. The purpose of the safety review is to ensure appropriate handling of these materials. During the safety review, all DoD laboratories involved in BSAT activities are responsible for ensuring the proper training of personnel on lab safety procedures; conducting necessary maintenance on equipment used to store or work with substances used within Biosafety Level 3 (BSL-3) laboratories; validating current Critical Reagents Program (CRP) catalog items, record-keeping, and inventories; reviewing and revising standard operating procedures; ensuring that those procedures are being followed; and ensuring that all materials associated with the CRP are properly accounted for. I am also directing that each of these laboratories review, in coordination with the Assistant Secretary of the Army for Acquisition, Logistics, and Technology, existing policies, procedures, and safety manuals to ensure their adequacy, to include seeking peer review of their laboratory safety manuals from other DoD laboratories. All laboratories will report back to me within ten days the results and findings of the safety review.

2. The moratorium on the production, work with, and shipment of inactivated anthrax put in place by the Deputy Secretary of Defense on 23 July remains in place, subject to the limited exceptions provided in that memorandum.

3. I have also determined that it is necessary to expand the moratorium above to the following:

   a. Dugway Proving Ground: No production, handling, testing, or shipment of any live or inactivated BSAT, derivatives of BSAT, or materials associated with the CRP.

   b. Edgewood Chemical and Biological Center, U.S. Army Medical Research Institute of Infectious Diseases, and the Naval Medical Research Center, Biological Defense Research Directorate: At these laboratories, I am directing the cessation of the production, handling, testing, or shipment of any materials associated with the CRP, including materials that have been inactivated. For inactivated BSL-3 or BSL-2 Bacillus species, there shall be no production, handling, testing, or shipment of these materials, except as required for the development of standardized, peer-reviewed, validated protocols for inactivation and viability testing. In
SUBJECT: Immediate Safety Review and Extension of Moratorium

addition, for all live or inactivated BSAT or derivatives of BSAT not associated with the CRP, there shall be no production or shipping of these materials without my approval.

4. Prior to resuming the activities prohibited above, laboratories must seek and receive my approval. I understand that these measures will affect ongoing research activities, and I expect to grant waivers in appropriate circumstances. Requests for exceptions should be sent to me through the Assistant Secretary of the Army for Acquisition, Logistics, and Technology.

JOHN M. McHUGH

CF: CHIEF OF STAFF, ARMY
ASSISTANT SECRETARY OF THE ARMY FOR ACQUISITION, LOGISTICS, AND TECHNOLOGY
ACTING GENERAL COUNSEL, ARMY